Related Experiment Video
Updated: Apr 18, 2026

Extracellular Glucose Depletion as an Indirect Measure of Glucose Uptake in Cells and Tissues Ex Vivo
Published on: April 6, 2022
Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo1, Ernest M Wright2, Volker Vallon3
1Glycation and Diabetes Complications Research Group, Mater Research Institute - University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia linda.gallo@mater.uq.edu.au.
Sodium-dependent glucose transporter 2 (SGLT2) inhibitors lower blood glucose by increasing urinary glucose excretion. Dual SGLT1/2 inhibitors are being developed for enhanced diabetes treatment.
Area of Science:
- Nephrology
- Endocrinology
- Pharmacology
Background:
- Traditional diabetes treatments can cause weight gain and hypoglycemia.
- Kidneys reabsorb glucose via sodium-dependent glucose transporters (SGLTs), primarily SGLT2 and SGLT1.
- Diabetes increases renal glucose reabsorption, contributing to hyperglycemia.
Purpose of the Study:
- To investigate the mechanism of SGLT2 inhibitors in lowering blood glucose.
- To explore the rationale for developing dual SGLT1/2 inhibitors.
- To assess the potential cardiovascular benefits of SGLT2 inhibitors.
Main Methods:
- Review of renal glucose reabsorption pathways.
- Analysis of SGLT2 inhibitor action on urinary glucose excretion.
- Discussion of dual SGLT1/2 inhibitor development.
Main Results:
- SGLT2 inhibitors enhance urinary glucose excretion, lowering blood glucose independently of insulin.
- SGLT2 inhibitors exhibit pleiotropic effects potentially reducing cardiovascular risk.
- SGLT1's role in glucose reabsorption explains limitations of SGLT2 inhibitors in normoglycemia.
Conclusions:
- SGLT2 inhibitors offer a novel approach to managing type 1 and type 2 diabetes.
- Dual SGLT1/2 inhibitors represent a potential advancement in diabetes therapy.
- Long-term studies are crucial to confirm the safety and cardiovascular benefits of SGLT2 inhibitors.
More Related Videos
08:03Glucose Uptake Measurement and Response to Insulin Stimulation in In Vitro Cultured Human Primary Myotubes
Published on: June 25, 2017
10:07Studying Diabetes Through the Eyes of a Fish: Microdissection, Visualization, and Analysis of the Adult tgfli:EGFP Zebrafish Retinal Vasculature
Published on: December 26, 2017
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Secondary Active Transport
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Glucose Absorption Into the Small Intestine
Type II Diabetes II: Pathophysiology